W. Fett

发表

Low‐dose recombinant interleukin‐2 therapy in advanced multiple myeloma

R. Hein, H. Wacker, H. Deicher, 1995, British journal of haematology.

Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis.

P. Fasching, W. Eiermann, S. Loibl, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

Marcus Schmidt, J. Huober, H. Lück, 2010, BMC Cancer.

Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial.

H. Sack, H. Makoski, J. Siewert, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Abstract P1-11-03: Pathological Complete Response after Neoadjuvant Chemotherapy + Trastuzumab Treatment Predicts Survival and Detects a Patient Subgroup at High Need for Improvement of Anti-HER2 Therapy. Three Year Median Follow-Up Data of the TECHNO Trial

P. Fasching, T. Kühn, R. Kreienberg, 2010 .

A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.

H. Deicher, M. Petit, R. Bartl, 1995, European journal of cancer.

PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer: A preplanned interim analysis of eff

P. Fasching, S. Loibl, I. Bauerfeind, 2008 .

Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy--a pilot study of the German Myeloma Treatment Group (GMTG).

H. Deicher, K. Schumacher, C. Klinkenstein, 1996, European journal of cancer.

First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study

A. Schneeweiss, V. Müller, O. Hoffmann, 2021, Breast.

hydroxyurea in chronic myelogenous leukemia . The German CML Randomized comparison of interferon-alpha with busulfan and

N. Schmitz, H. Heimpel, L. Kanz, 2002 .

Randomized Comparison of Interferon-a With Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia

N. Schmitz, H. Heimpel, L. Kanz, 2002 .

Karyotype in multiple myeloma and plasma cell leukaemia.

D. Hossfeld, W. Fiedler, H. Weh, 1993, European journal of cancer.

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

P. Fasching, T. Kühn, R. Kreienberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery.

N Harbeck, W Fett, S Loibl, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosi

N Harbeck, W Fett, S Loibl, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma

P. Fasching, C. Denkert, S. Loibl, 2014, Breast Cancer Research and Treatment.

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

P. Fasching, W. Eiermann, S. Loibl, 2010, Breast Cancer Research and Treatment.

Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.

N. Schmitz, H. Heimpel, M. Griesshammer, 1996, Bone marrow transplantation.

Abstract P4-14-04: AVANTI: A non-interventional study examining the combination of bevacizumab with paclitaxel or capecitabine in metastatic breast cancer

A. Schneeweiss, V. Müller, S. Fruehauf, 2013 .

Abstract P4-13-26: Efficacy, safety, and treatment decision-making in the AVANTI German observational study of first-line bevacizumab (BEV)-containing therapy for locally advanced, recurrent, or metastatic breast cancer (aBC)

A. Schneeweiss, V. Müller, P. Klare, 2016 .